Supporting Information

Association of COVID-19 risk factors with systemic fungal infections in hospitalized patients

Abbygail C. Wilbourn,^{a,*} Oleg V. Tsodikov,^{a,*} and Sylvie Garneau-Tsodikova ^{a,*}

^a University of Kentucky, College of Pharmacy, 789 South Limestone St., Lexington, KY,

40536-0596, USA.

* Correspondence to: spency05@gmail.com or oleg.tsodikov@uky.edu or sylviegtsodikova@uky.edu




Figure S1. The age distribution of the patients. **A.** The age distribution in the non-infected group (pink bars). **B.** The age distribution in the infected group (orange bars).




Figure S2. The incidence of systemic fungal infections in this study, grouped by the fungal pathogen.

Tables

	4,952 COVID-19 patients without fungal	47 COVID-19 patients with fungal	
	infection	infection	
Gender, male n (%), $p = 0.194$	2267 (46%)	26 (55%)	
Race, white n (%)*, $p = 0.009$	3734 (75%)	44 (94%)	
Median age in years (IQR)*, p <0.001	41 (35)	67 (18)	
Median height in cm (IQR), $p = 0.227$	170.0 (15.3)	170.1 (13.4)	
Median weight in kg (IQR), $p = 0.745$	85.2 (32.6)	87.6 (33.7)	
Admit to ICU, n, (%)*, p <0.001	222 (4%)	20 (43%)	
Transferred from another hospital, n (%)*, p <0.001	572 (12%)	30 (64%)	
Median length of hospital stay in h (IQR)*, p <0.001	12 (34)	524 (575)	
Abbreviations: ICU = intensive care unit, IQR = interqua	artile range.		
* = statistically significant difference between the two gr	roups		

Table S2. Clinical characteristics of the patients without and with systemic fungal infections.			
	4,952 COVID-19 patients without	47 COVID-19 patients with fungal	
	fungal infection	infection	
Mechanically ventilated hospitalizations, n (%)*, p <0.001	339 (6.8%)	29 (62%)	
Median duration of mechanical ventilation, h (IQR)*, p < 0.001	208 (316)	488 (579)	
Diabetes mellitus, n (%)*, p <0.001	616 (12%)	24 (51%)	
Cardiovascular disease, n (%)*, p <0.001	684 (14%)	26 (55%)	
Obesity, n (%)*, p <0.001	337 (7%)	14 (28%)	
Mortality, n (%)*, p < 0.001			
In hospital*, OR = 11.0 (95% C.I.: 5.9-20.7)	202 (4%)	15 (32%)	
30-day post-discharge*, OR = 12.1 (95% C.I.: 6.5-22.2)	222 (4.5%)	17 (36%)	
90-day post-discharge*, OR = 12.3 (95% C.I.: 6.8-22.6)	237 (4.8%)	18 (38%)	
* = statistically significant difference between the two groups; OR = odds ratio; C.I. = confidence interval.			

Table S3. COVID-19 therapy administrations.				
	4,952 COVID-19 patients without fungal infection		47 COVID-19 patients with fungal infection	
COVID therapy	Administrations (per patient)	Patients (%)	Administrations (per patient)	Patients (%)
Remdesivir	2914 (5)	590 (12%)	110 (6)	18 (32%)
Tocilizumab	27 (1)	27 (0.5%)	0 (0)	0 (0)
Dexamethasone	5472 (7)	831 (17%)	357 (11)	32 (68%)
Prednisone	1131 (8)	138 (3%)	141 (11)	13 (28%)
Methylprednisolone	2059 (14)	153 (3%)	213 (18)	12 (26%)
Fludrocortisone	140 (7)	21 (0.4%)	12 (4)	3 (6%)
Hydrocortisone	1119 (10)	109 (2%)	227 (18)	13 (28%)
Prednisolone	12 (6)	2 (0.04%)	0 (0)	0 (0)

	4,952 COVID-19 patients without fungal infection	47 COVID-19 patients with fungal infection
Total mg median (IQR)*, p <0.001	42 (48)	95.25 (257)
Max total mg	2209	1081.5
Min total mg	1.5	7.5
Total administrations median (IQR)*, p <0.001	7 (7)	13 (28.25)
Max total administrations	225	92
Min total administrations	1	1
* = statistically significant difference.		

Table S5. The SARS-CoV-2 vaccination status.				
	4,952 COVID-19 patients without fungal infection		47 COVID-19 patients	with fungal infection
Vaccine manufacturer	All vaccinations	Patients (%)	All vaccinations	Patients (%)
Pfizer-BioNTech	409	308 (6.2%)	0	0
Moderna	152	111 (2.2%)	0	0
Janssen	5	5 (0.1%)	0	0

Table S6. Predictors of systemic fungal infections in hospitalized COVID-19 patients.				
Predictor	OR all infections	OR candidiasis	OR aspergillosis	
Age, ≥50/<50	7.9 (3.7-16.9) ^a , p <0.001	16 (5-51), p < 0.001	14 (2-114), p = 0.011	
Race, white/other	4.8 (1.5-15.4), p = 0.009	4.9 (1.2-20.4), p = 0.03	p = 0.3	
ICU admission	16 (9-29), p < 0.001	12 (6-26), p < 0.001	81 (17-385), p <0.001	
Mechanical ventilation status	22 (12-40), p < 0.001	17 (8-34), p < 0.001	51 (11-243), p <0.001	
Length of hospital stay, ≥13 days/<13 days	42 (21-83), p < 0.001	32 (15-70), p < 0.001	+∞;* all infected patients ≥13 d	
Diabetes mellitus	7.3 (4.1-13.1), p < 0.001	7.0 (3.5-14.0), p < 0.001	10 (3-37), p < 0.001	
Cardiovascular disease	7.7 (4.3-13.8), p < 0.001	9.0 (4.4-18.4), p < 0.001	4.0 (1.1-14.4), p < 0.031	
Obesity	5.8 (3.1-11.0), p < 0.001	6.2 (2.9-13.1), p < 0.001	8.9 (2.5-31.8), p = 0.001	
Remdesivir	5.0 (2.8-9.0), p < 0.001	4.4 (2.1-9.0), p < 0.001	11 (3-39), p <0.001	
Steroids (any administration of any steroid)	23 (10-52), p <0.001	14 (6-33), p <0.001	+∞;* all infected patients + steroids	
Lack of COVID-19 vaccination	+∞;* all infected patients	+∞;* all infected patients	+∞;* all infected patients – vaccine	
*The OR ranges correspond to 95% confidence intervals.				

^{*}The statistical significance and the OR range could not be calculated due to the lack of patients or only one patient in one of the categories.